Paul Tudor Jones Moon Lake Immunotherapeutics Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 31,840 shares of MLTX stock, worth $1.68 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
31,840
Previous 27,173
17.18%
Holding current value
$1.68 Million
Previous $1.19 Million
34.42%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding MLTX
# of Institutions
124Shares Held
58.2MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$1.15 Billion34.86% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$447 Million30.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.98MShares$157 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$146 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$122 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.94B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...